Shots:

• The P-III NAVIGATOR study involves assessing Tezepelumab + SOC vs PBO +SOC in adults (18–80yrs.old) and adolescents (12–17yrs. old) with severe- uncontrolled asthma. The study showed improvements in lung function and nasal polyp symptoms
• The pre-specified exploratory analysis evaluated the effect of tezepelumab in NAVIGATOR patients with/ out reported nasal polyps (NP+ or NP−) in the past 2yrs. The analysis showed an 86% reduction in the AAER in NP+ patients & 52% in NP− patients over 52wks.
• Other results include an increase in pre-bronchodilator FEV1 (0.20 L vs 0.13 L)- 9.6 points reduction in SNOT-22 score in NP+ patients (21.5 vs 19.0)- The results were published at ERS 2021

  | Ref: AstraZeneca | Image: Business Standard